利用人工智能推进嵌合抗原受体T细胞疗法：机遇与挑战
Advancing CAR T-cell Therapies with Artificial Intelligence: Opportunities and Challenges.
作者信息
Luciani Fabio, Safavi Arman, Guruprasad Puneeth, Chen Linhui, Ruella Marco
机构信息
Systems Immunology and Immunogenomics, School of Biomedical Sciences, UNSW Sydney, Sydney, Australia.
Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
出版信息
Blood Cancer Discov. 2025 May 5;6(3):159-162. doi: 10.1158/2643-3230.BCD-23-0240.
Abstract
Artificial intelligence could enhance chimeric antigen receptor T-cell therapy outcomes through optimization of all steps, from target identification, vector design, and manufacturing to personalized data-driven clinical decisions. In this report, we highlight steps toward unlocking this potential, including the need for standardized, comprehensive data repositories as a way for addressing barriers to artificial intelligence learning, such as data heterogeneity and patient privacy.
摘要
人工智能可以通过优化从靶点识别、载体设计、制造到个性化数据驱动的临床决策等所有步骤，提高嵌合抗原受体T细胞疗法的疗效。在本报告中，我们强调了释放这一潜力的步骤，包括需要标准化、全面的数据存储库，以此作为解决人工智能学习障碍（如数据异质性和患者隐私）的一种方式。
相似文献
1
Advancing CAR T-cell Therapies with Artificial Intelligence: Opportunities and Challenges.利用人工智能推进嵌合抗原受体T细胞疗法：机遇与挑战
Blood Cancer Discov. 2025 May 5;6(3):159-162. doi: 10.1158/2643-3230.BCD-23-0240.
2
CAR-T therapy-based innovations in the enhancement of contemporary anti-tumor therapies.基于嵌合抗原受体T细胞（CAR-T）疗法的创新在当代抗肿瘤治疗增强方面的应用。
Front Immunol. 2025 Jul 2;16:1622433. doi: 10.3389/fimmu.2025.1622433. eCollection 2025.
3
Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies.嵌合抗原受体T细胞疗法治疗癌症后的神经精神表现：临床结局与管理策略的系统评价
J Immunother Cancer. 2024 Dec 22;12(12):e009174. doi: 10.1136/jitc-2024-009174.
4
A bibliometric analysis of challenges and advancements in the integrated application of nanoparticles and chimeric antigen receptor T cell therapy.纳米颗粒与嵌合抗原受体T细胞疗法联合应用的挑战与进展的文献计量分析
Hum Vaccin Immunother. 2025 Dec;21(1):2518634. doi: 10.1080/21645515.2025.2518634. Epub 2025 Jun 17.
5
Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.嵌合抗原受体 (CAR) T 细胞疗法治疗复发或难治性弥漫性大 B 细胞淋巴瘤患者。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2.
6
Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors.通过工程化 PGC-1α 进行代谢重编程可改善针对实体瘤的人嵌合抗原受体 T 细胞疗法。
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-006522.
7
Transduction of γδ T cells with Baboon envelope pseudotyped lentiviral vector encoding chimeric antigen receptors for translational and clinical applications.用编码嵌合抗原受体的狒狒包膜假型慢病毒载体转导γδ T细胞，用于转化研究和临床应用。
Front Immunol. 2025 Jun 6;16:1548630. doi: 10.3389/fimmu.2025.1548630. eCollection 2025.
8
CAR-T Cells Therapy in Glioblastoma: A Systematic Review on Molecular Targets and Treatment Strategies.嵌合抗原受体 T 细胞疗法治疗胶质母细胞瘤：分子靶点和治疗策略的系统评价。
Int J Mol Sci. 2024 Jun 29;25(13):7174. doi: 10.3390/ijms25137174.
9
Revaccination following CAR-T therapy: a needs assessment.嵌合抗原受体T细胞（CAR-T）疗法后的再次接种疫苗：需求评估
Hematology. 2025 Dec;30(1):2519865. doi: 10.1080/16078454.2025.2519865. Epub 2025 Jun 23.
10
Therapeutic advantage of combinatorial chimeric antigen receptor T cell and chemotherapies.嵌合抗原受体T细胞与化疗联合治疗的优势
Pharmacol Rev. 2025 Jan;77(1):100011. doi: 10.1124/pharmrev.124.001070. Epub 2024 Nov 22.
引用本文的文献
1
Overcoming Immune Barriers in Allogeneic CAR-NK Therapy: From Multiplex Gene Editing to AI-Driven Precision Design.克服异基因CAR-NK疗法中的免疫障碍：从多重基因编辑到人工智能驱动的精准设计
Biomolecules. 2025 Jun 26;15(7):935. doi: 10.3390/biom15070935.
2
Case Report: Combined umbilical cord blood and peripheral blood stem cell transplantation with donor lymphocyte infusion for R/R AML post CAR-CLL1 failure.病例报告：在嵌合抗原受体（CAR）-CLL1治疗失败后的复发/难治性急性髓系白血病（R/R AML）中，联合脐血和外周血干细胞移植及供体淋巴细胞输注
Front Immunol. 2025 Jun 5;16:1598754. doi: 10.3389/fimmu.2025.1598754. eCollection 2025.
3
Radiomic Features Prognosticate Treatment Response in CAR-T Cell Therapy.放射组学特征可预测CAR-T细胞疗法的治疗反应。
Cancers (Basel). 2025 May 30;17(11):1832. doi: 10.3390/cancers17111832.
本文引用的文献
1
Rapid in silico directed evolution by a protein language model with EVOLVEpro.通过带有EVOLVEpro的蛋白质语言模型进行快速计算机辅助定向进化。
Science. 2025 Jan 24;387(6732):eadr6006. doi: 10.1126/science.adr6006.
2
CAR and CAR T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies.在 B 细胞恶性肿瘤患者输注 CD19 CAR T 细胞后，CAR 和 CAR T 细胞沿着 NK 样细胞亚群的分化轨迹发展。
Nat Commun. 2023 Nov 27;14(1):7767. doi: 10.1038/s41467-023-43656-7.
3
Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia.单细胞转录组图谱指导 CAR-T 细胞治疗急性髓系白血病的发展。
Nat Biotechnol. 2023 Nov;41(11):1618-1632. doi: 10.1038/s41587-023-01684-0. Epub 2023 Mar 13.
4
Deconvolution of clinical variance in CAR-T cell pharmacology and response.脱卷积 CAR-T 细胞药代动力学和反应中的临床变异性。
Nat Biotechnol. 2023 Nov;41(11):1606-1617. doi: 10.1038/s41587-023-01687-x. Epub 2023 Feb 27.
5
CAR immune cells: design principles, resistance and the next generation.嵌合抗原受体（CAR）免疫细胞：设计原理、抗性与下一代产品
Nature. 2023 Feb;614(7949):635-648. doi: 10.1038/s41586-023-05707-3. Epub 2023 Feb 22.
6
Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning.利用组合信号基序文库和机器学习解码 CAR T 细胞表型。
Science. 2022 Dec 16;378(6625):1194-1200. doi: 10.1126/science.abq0225. Epub 2022 Dec 8.
7
Post-infusion CAR T cells identify patients resistant to CD19-CAR therapy.输注后嵌合抗原受体 T 细胞可鉴定出对 CD19-CAR 治疗产生耐药的患者。
Nat Med. 2022 Sep;28(9):1860-1871. doi: 10.1038/s41591-022-01960-7. Epub 2022 Sep 12.
8
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma.与 CAR-T 疗法治疗难治性 B 细胞淋巴瘤反应相关的独特细胞动力学。
Nat Med. 2022 Sep;28(9):1848-1859. doi: 10.1038/s41591-022-01959-0. Epub 2022 Sep 12.
9
Toward Rapid, Widely Available Autologous CAR-T Cell Therapy - Artificial Intelligence and Automation Enabling the Smart Manufacturing Hospital.迈向快速、广泛可用的自体嵌合抗原受体T细胞疗法——人工智能与自动化助力智能制造医院
Front Med (Lausanne). 2022 Jun 6;9:913287. doi: 10.3389/fmed.2022.913287. eCollection 2022.
10
Predicting T-cell quality during manufacturing through an artificial intelligence-based integrative multiomics analytical platform.通过基于人工智能的综合多组学分析平台预测制造过程中的T细胞质量。
Bioeng Transl Med. 2022 Jan 4;7(2):e10282. doi: 10.1002/btm2.10282. eCollection 2022 May.
Zotero 插件